Dorzolamide
- Generic Name
- Dorzolamide
- Brand Names
- Cosopt, Trusopt
- Drug Type
- Small Molecule
- Chemical Formula
- C10H16N2O4S3
- CAS Number
- 120279-96-1
- Unique Ingredient Identifier
- 9JDX055TW1
- Background
Dorzolamide is a non-bacteriostatic sulfonamide derivative and topical carbonic anhydrase (CA) inhibitor that treats elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. It works by blocking an enzyme in the ciliary process that regulates ion balance and fluid pressure in the eyes. Unlike oral CA inhibitors, dorzolamide has negligible effects of acid-base or electrolyte disturbances and other systemic adverse effects. First marketed in 1995, dorzolamide is available in ophthalmic solutions as monotherapy marketed as Trusopt or in combination with timolol as Cosopt PF.
- Indication
Dorzolamide is indicated for the management of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. It can also be used in combination with timolol for the same indication in patients who are insufficiently responsive to ophthalmic beta-blockers.
Its pre-operative use was also investigated to prevent elevated intraocular pressure after neodynium yttrium aluminum garnet laser posterior capsulotomy.
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Ocular Hypertension
Comparison of Intraocular Pressure (IOP)-Lowering Efficacy and Safety of AZORGA® Ophthalmic Suspension and COSOPT® Ophthalmic Solution
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- Drug: Subject's habitual PGA monotherapy
- First Posted Date
- 2014-12-25
- Last Posted Date
- 2016-12-08
- Lead Sponsor
- Alcon, a Novartis Company
- Target Recruit Count
- 218
- Registration Number
- NCT02325518
- Locations
- 🇯🇵
Contact Alcon Japan Ltd. for Trial Locations, Tokyo, Japan
Efficacy of Dorzolamide as an Adjuvant After Focal Photocoagulation in Clinically Significant Macular Edema
- Conditions
- Diabetic RetinopathyDiabetic Macular Edema
- Interventions
- Drug: Placebo Sodium hyaluronate 4mg
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2015-03-20
- Lead Sponsor
- Hospital Juarez de Mexico
- Target Recruit Count
- 60
- Registration Number
- NCT02227745
- Locations
- 🇲🇽
Hospital Juarez de Mexico, Mexico City, Mexico
Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma
- First Posted Date
- 2012-02-07
- Last Posted Date
- 2019-09-27
- Target Recruit Count
- 37
- Registration Number
- NCT01527682
- Locations
- 🇮🇹
Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy
🇮🇹A.O. Universitaria " Policlinico Vittorio Emanuele" P.O. Rodolico, Catania, Italy
Patient Preference Comparison of AZARGA Versus COSOPT
- Conditions
- Open-Angle GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2011-04-21
- Last Posted Date
- 2014-02-10
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 112
- Registration Number
- NCT01340014
Safety and Efficacy of Triple Combination Therapy With Dorzolamide Hydrochloride / Brimonidine Tartrate / Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2013-07-18
- Lead Sponsor
- Allergan
- Registration Number
- NCT01284166
Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy
- Conditions
- Macular HoleRetinal Detachment
- Interventions
- First Posted Date
- 2010-12-10
- Last Posted Date
- 2019-09-04
- Lead Sponsor
- Mid Atlantic Retina
- Target Recruit Count
- 21
- Registration Number
- NCT01257698
- Locations
- 🇺🇸
Wills Eye Institute, Philadelphia, Pennsylvania, United States
Comparison of the Efficacy of AZARGA® Versus COSOPT® in Patients With Open-Angled Glaucoma or Ocular Hypertension
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2010-04-28
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- Alcon Research
- Target Recruit Count
- 70
- Registration Number
- NCT01111890
A Comparison of the Effect of Dorzolamide and Timolol on Optic Disk Blood Flow in Patients With Open Angle Glaucoma
- First Posted Date
- 2009-10-08
- Last Posted Date
- 2009-10-08
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 160
- Registration Number
- NCT00991822
- Locations
- 🇦🇹
Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria
The DIOXXACT Trial(Diurnal IOP and OBF Xalatan vs Xalatan And Cosopt Trial)
- First Posted Date
- 2009-08-12
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- Maisonneuve-Rosemont Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT00957190
- Locations
- 🇨🇦
Maisonneuve-Rosemont Hospital, Montreal, Quebec, Canada
Effect of Myocilin Genetic Variants on Intraocular Pressure and Pressure Variation in Sitting and Supine Positions
- Conditions
- Glaucoma
- Interventions
- First Posted Date
- 2009-05-21
- Last Posted Date
- 2017-06-02
- Lead Sponsor
- University of Michigan
- Target Recruit Count
- 14
- Registration Number
- NCT00906087
- Locations
- 🇺🇸
W.K. Kellogg Eye Center, Ann Arbor, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.